Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 2/20 | 0.30 |
| ▸ | GABRD | O14764 | 2/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.30 |
| ▸ | GABRE | P78334 | 2/20 | 0.30 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.30 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10046223 | 1.00 | DPP4 (0.32) | DPP4DPP8DPP9GFPT1CYP2D6 | |
| SCHEMBL10046221 | 1.00 | DPP4 (0.32) | DPP4DPP8DPP9GFPT1CYP2D6 | |
| SCHEMBL19891849 | 0.83 | DPP4 (0.33) | DPP4DPP8DPP9 | |
| SCHEMBL18821637 | 0.83 | — | — | |
| SCHEMBL10046241 | 0.82 | CYP2D6 (0.32) | CYP2D6CYP2C19 | |
| SCHEMBL10046240 | 0.82 | CYP2D6 (0.32) | CYP2D6CYP2C19 | |
| SCHEMBL10046239 | 0.82 | CYP2D6 (0.32) | CYP2D6CYP2C19 | |
| SCHEMBL25132012 | 0.81 | ANPEP (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL12132309 | 0.81 | ANPEP (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL13363467 | 0.81 | ANPEP (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911412-B2 | Derivatized chitosan polymers and methods of treating vascular disorders | SYNEDGEN, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11786547-B2 | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds | SYNEDGEN, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786547-B2 | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds | SYNEDGEN, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | SYNEDGEN, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | SYNEDGEN, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230201248-A1 | COMPOSITIONS AND METHODS OF USE THEREOF | SYNEDGEN, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230201248-A1 | COMPOSITIONS AND METHODS OF USE THEREOF | SYNEDGEN, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230181623-A1 | COMPOSITIONS AND METHODS OF USE FOR WOUND HEALING | SYNEDGEN, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230021050-A1 | COMPOSITIONS AND METHODS OF THEIR USE | SYNEDGEN, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220160754-A1 | DERIVATIZED CHITOSAN POLYMERS AND METHODS OF TREATING VASCULAR DISORDERS | SYNEDGEN, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20120295355-A1 | NUCLEIC ACID DELIVERY USING MODIFIED CHITOSANS | BAKER SHENDA (US) | 2012-11-22 | — | — | US | disclosed |
| US-8119780-B2 | Chitosan-derivative compounds and methods of controlling microbial populations | SYNEDGEN, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| WO-2011028968-A1 | ORAL CARE METHODS AND COMPOSITIONS UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | SYNEDGEN, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011028967-A1 | METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | SYNEDGEN INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20100137193-A1 | CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH | SYNEDGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100130443-A1 | CHITOSAN DERIVATIVES, COMPOSITIONS AND RELATED METHODS OF USE | SYNEDGEN INC. (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010056927-A1 | CHITOSAN DERIVATIVES ALONE OR IN COMBINATION FOR THE TREATMENT OF MDR MICROBIAL INFECTIONS | SYNEDGEN, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100056474-A1 | Methods and Compositions for the Prevention of and Treatment of Infections Utilizing Chitosan-Derivative Compounds | UNITED STATES GOVERNMENT | 2010-03-04 | — | — | US | disclosed |
| WO-2010021930-A1 | PREVENTION AND TREATMENT OF MRSA INFECTIONS WITH CHITOSAN-DERIVATIVES | SYNEDGEN, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20070281904-A1 | Chitosan-derivative compounds and methods of controlling microbial populations | UNITED STATES GOVERNMENT | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181623-A1 | COMPOSITIONS AND METHODS OF USE FOR WOUND HEALING | PARG, ARGLU1, AREG | DPP4 2000/4885DPP8 1362/4885DPP9 971/4885 |
| US-20100137193-A1 | CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH | CHIT1, CHIA, ALG1 | DPP4 499/4885DPP8 724/4885DPP9 401/4885 |
| US-20220160754-A1 | DERIVATIZED CHITOSAN POLYMERS AND METHODS OF TREATING VASCULAR DISORDERS | CHIA, CHI3L1, CHI3L2 | DPP4 1065/4885DPP8 838/4885DPP9 860/4885 |
| US-20100056474-A1 | Methods and Compositions for the Prevention of and Treatment of Infections Utilizing Chitosan-Derivative Compounds | NRDC, ARG1, CHIA | DPP4 1129/4885DPP8 1401/4885DPP9 355/4885 |
| US-20230021050-A1 | COMPOSITIONS AND METHODS OF THEIR USE | ARG1, ARG2, FUT6 | DPP4 1375/4885DPP8 1860/4885DPP9 2354/4885 |
| US-20070281904-A1 | Chitosan-derivative compounds and methods of controlling microbial populations | ARG1, NRDC, CHIA | DPP4 111/4885DPP8 538/4885DPP9 201/4885 |
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | CHIA, MMP8, CHIT1 | DPP4 778/4885DPP8 873/4885DPP9 764/4885 |
| US-20230201248-A1 | COMPOSITIONS AND METHODS OF USE THEREOF | ENGASE, FUT5, ALG1 | DPP4 913/4885DPP8 1136/4885DPP9 947/4885 |
| US-11786547-B2 | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds | CHIT1, ALG1, CSGALNACT1 | DPP4 1777/4885DPP8 1609/4885DPP9 1243/4885 |
| US-20100130443-A1 | CHITOSAN DERIVATIVES, COMPOSITIONS AND RELATED METHODS OF USE | CHIT1, CHIA, ALG1 | DPP4 1189/4885DPP8 1505/4885DPP9 546/4885 |
| US-11911412-B2 | Derivatized chitosan polymers and methods of treating vascular disorders | CHIA, CHI3L1, CHI3L2 | DPP4 1065/4885DPP8 838/4885DPP9 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.